For men with metastatic prostate cancer refractory to hormonal and chemotherapy, what is the efficacy and toxicity of radionuclide therapy with Lutetium-177 PSMA
Latest Information Update: 31 Mar 2022
Price :
$35 *
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LuPSMA
- 19 Feb 2022 Results assessing improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer presented at the 2022 Genitourinary Cancers Symposium
- 16 Feb 2019 Updated results (Data cut-off: 5 Oct 2018) presented at the 2019 Genitourinary Cancers Symposium
- 05 Jun 2018 Interim results (n=50) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.